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Abstract
Lung fibrosis is the final common pathway of a large variety of chronic lung disorders, named interstitial lung
diseases. The most aggressive form is the idiopathic pulmonary fibrosis [IPF] characterized by alveolar epithelial cell
injury/activation, expansion of the fibroblast/myofibroblast population, and the exaggerated accumulation of
extracellular matrix [ECM] components which ultimately result in the destruction of the lung parenchyma. Several
matrix metalloproteases [MMPs] are upregulated in the IPF lungs and have been shown to actively participate in
the pathogenesis of the disease through extracellular matrix remodeling and basement membrane disruption.
However, MMPs can also breakdown molecules that mediate cell-cell and cell-ECM interactions, and can activate
growth factors and growth factor receptors indicating that they likely contribute to other local biopathological
processes such as apoptosis, migration, proliferation and angiogenesis.
Introduction
Idiopathic Pulmonary Fibrosis
Lung fibrosis is the final result of a large and heteroge-
neous group of lung disorders, known as interstitial lung
diseases (ILD) [1]. One of the most common and unques-
tionably the most aggressive ILD is idiopathic pulmonary
fibrosis (IPF) with its histopathologic pattern of usual
interstitial pneumonia (UIP) [1,2]. IPF is a chronic, pro-
gressive, irreversible and usually lethal lung disease of
unknown etiology, with a median survival of 2-3 years
from diagnosis in affected patients.
Most patients are between 50-70 years old and the fre-
quency of the disease increases markedly with age. How-
ever, the mechanisms linking aging with the disease
remain elusive. Its histological hallmark, UIP, is character-
ized by a variegated appearance [temporal heterogeneity]
resulting from irregular juxtaposition of fibrotic scarring,
honeycomb change, some interstitial inflammation and
normal lung [3].
IPF seems to have a long asymptomatic period, where
alveolar epithelial cell microinjuries and activation are
occurring in different small areas of the both lungs, pri-
marily in the basal and subpleural regions. After a time,
the anatomical and functional magnitude of the lesions
reach a threshold, and the symptoms [primarily dys-
pnea] become visible.
Most evidence indicates that epithelial cells are critical
in the initiation and progression of the disease. Thus, aber-
rantly activated alveolar/bronchiolar cells produce the
cytokines and growth factors responsible for the migration
and proliferation of local fibroblasts [e.g. platelet derived
growth factor (PDGF)], as well as of circulating fibrocytes
(e.g. CXCL12) and its transition to myofibroblasts, usually
through the secretion of transforming growth factor beta-
1( T G F b1) [1,4-6]. In addition, avb6 an integrin which is
able to activate latent TGF-b and that is expressed at low
or undetectable levels in normal lungs is strongly upregu-
lated in IPF within epithelial cells lining the alveolar ducts
and alveoli [7].
Also, epithelial cells contribute to the expansion of the
fibroblast population through the epithelial to mesenchy-
mal transition (EMT) as it has been demonstrated with
three different approaches in IPF lungs [8-10]. Turning an
epithelial cell into a mesenchymal cell requires a profound
change in genetic and epigenetic programs leading to
alterations in morphology, cellular architecture, adhesion,
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dence indicates that tumor-associated matrix metallopro-
teases (MMPs) can stimulate processes associated with
EMT. Thus, it has been shown that the exposure of mouse
mammary epithelial cells to MMP-3 stimulates epithelial-
mesenchymal transition [12]. Likewise, other MMPs, such
as MMP-2 and MMP-9 mediated E-cadherin disruption as
a key step in epithelial tubular cell EMT indicating that
may be also implicated in the fibrotic response [13]. More-
over, recent data indicate that MMP-9 has a higher capa-
city than that of Snail in eliciting the development of EMT
[14].
Independently of their origin, fibroblasts and myofibro-
blasts accumulate as small clusters (foci) in subepithelial
areas arranged in a linear fashion within a pale staining
matrix. Overlying epithelium consists of hyperplastic
pneumocytes or columnar non-ciliated bronchiolar cells
[3]. Finally, these mesenchymal cells secrete exaggerated
amounts of extracellular matrix molecules, primarily
fibrilar collagens that provoke an extensive structural dis-
organization in the lung microenvironment where alveo-
lar-capillary units are lost and replaced by scarring and
cysts [honeycombing]. Importantly, many of the pro-
cesses that result in this severe architectural remodeling
involve an uncoordinated regulation and expression of
several matrix metalloproteases.
Matrix Metalloproteases
MMPs are the M10 family of endopeptidases that belong
to the MA zinc-containing clan of metallopeptidases and
to the metzincin subclan of proteases [15,16]. In humans
the MMPs family consists of 23 members that are codified
in 24 genes including duplicated MMP-23 genes [17].
Most of the MMPs are secreted enzymes, although there
are some membrane types MMPs (MT-MMPs). Impor-
tantly however, some of the secreted MMPs have been
found inside the cell and probably acting on intracellular
substrates [18,19].
According to their structural and functional characteris-
tics, MMPs family members have been classified into six
subgroups that include: collagenases, gelatinases, stromely-
sins, matrilysins, membrane-type MMPs (MT-MMPs),
and other MMPs [20]. Based on structure MMPs have
been also classified as archetypal MMPs, matrilysins, gela-
tinases, and furin activable MMPs [21].
MMPs are tightly regulated at the transcriptional and
post-transcriptional levels and their expression, usually
low or undetectable under physiological conditions,
increased under some processes such as wound healing
[22]. After secretion, MMPs are also regulated by activa-
tion of the precursor zymogens and by inhibition through
endogenous inhibitors, tissue inhibitors of metallopro-
teases (TIMPs). Uncontrolled MMP activity results in tis-
sue damage and functional alterations.
The contribution of MMPs to extracellular matrix remo-
deling is complex. They are not only responsible of matrix
degradation but also may contribute processing a variety
of bioactive mediators such as growth factors, cytokines,
chemokines, and cell-surface-receptors modulating their
activity either by direct cleavage, or releasing them from
extracellular matrix bound stores.
MMP-1 and MMP-7 are strongly upregulated in idiopathic
pulmonary fibrosis
The transcriptional signature and immunohistochemical
analyses of IPF lungs have revealed that several MMPs,
primarily MMP1 and MMP7 are among the molecules
that are more significantly overexpressed compared with
control lungs [16,23] (Figure 1).
MMP1 is increased despite the progressive accumulation of
fibrillar collagens
MMP1, also known as collagenase-1, is the archetype of
MMPs capable of degrading types I and III fibrillar col-
lagens. Therefore, its over-expression in IPF lungs, where
interstitial collagens are progressively depositing is an
unsolved paradox. Furthermore, excessive MMP-1 is
involved in diseases that, in contrast to fibrosis, are charac-
terized by exaggerated extracellular matrix degradation,
such as rheumatoid arthritis and lung emphysema [24,25].
A possible explanation for this paradox was revealed by
the observation that in IPF lungs the enzyme is expressed
primarily by epithelial cells whereas is virtually absent in
the fibroblastic foci where the interstitial collagens are
being secreted [26,27].
The role of the epithelial expression of MMP1 in IPF is
presently unknown, although it might contribute to the
formation of the cystic spaces (honeycombing), character-
istic of this disorder. The strong epithelial expression of
MMP1 in IPF lungs might be also implicated in cell migra-
tion as occurs in skin wound healing [28].
Given the prominent upregulation of this enzyme in IPF
lungs, we recently tested the frequency of the 2G/2G gen-
otype at -1,607, which is associated with increased gene
expression, in a cohort of IPF patients. We found that this
genotype is increased in the patients with this disease, but
additionally, by sequencing the MMP-1 promoter we
revealed a putative gene-environment interaction between
the T/G SNP at position -755 and smoking in this disease
[29]. This is an important finding because several studies
performed in sporadic or familial cases of IPF have shown
that smoking is considered a strong risk factor of IPF [6].
MMP7 is one of the genes most consistently increased in
idiopathic pulmonary fibrosis
Several studies indicate that dysregulation of MMP-7 is
associated with IPF [23,30,31]. Similar to MMP-1, the
increased immunoreactive protein is also found primarily
expressed by the abnormal alveolar epithelium [23].
However, the excessive production of MMP-7 has been
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the MMP7 null mouse is protected from bleomycin-
induced lung fibrosis [23]. The profibrotic role of MMP7
might be multiple considering its broad substrate specifi-
city that includes basement membrane and extracellular
matrix components. Additionally, this enzyme processes
numerous bioactive substrates including FAS ligand, b4
integrin, E-cadherin, pro-HB-epidermal growth factor,
plasminogen, pro-TNF-a, syndecan, and insulin growth
factor binding protein-3 (IGFBP-3), and diverse studies
support a role for this enzyme in apoptosis, inflammation
and innate immunity.
Interestingly, in the alveolar epithelial cells of IPF lungs
MMP7 colocalize with osteopontin, and application of
weakest link statistical model to microarray data indicate a
significant interaction between both molecules suggesting
that this interaction may have an important effect on the
IPF development [30]. This hypothesis is supported by the
findings that MMP7 is induced and activated by osteopon-
tin while the later is cleaved and activated by MMP7 [32].
Interestingly, the analysis of renal tissue gene expression
associated with aging MMP-7 has been found among the
genes significantly up-regulated in very old kidneys that
showed higher rates of histopathological changes including
glomerulosclerosis and interstitial fibrosis [33]. This is an
important finding since as mentioned IPF is considered an
aging-related lung disease [6].
MMP-1 and MMP-7 may serve as diagnostic biomarkers
Regardless their effects in the architectural remodeling in
IPF lungs, MMP-1 and MMP-7 may play a role as biomar-
kers for the differential diagnosis. Thus, in a recent study it
was found that both enzymes are significantly higher in
the serum of patients with IPF compared to patients with
hypersensitivity pneumonitis, sarcoidosis and chronic
obstructive pulmonary disease [34]. A similar trend in
gene expression of MMP7 and MMP1 is found in the
lungs of patients with IPF and HP, supporting the notion
that the changes in peripheral blood concentrations are
reflective of the lung gene environment and constitute a
disease-specific signal. Moreover, levels of circulating
MMP-7 appeared to predict outcome since MMP7 higher
concentrations of this enzyme negatively correlated with
percent predicted forced vital capacity and percent pre-
dicted carbon monoxide diffusing capacity.
MMP- 3 may contribute to epithelial-mesenchymal
transition
Recently, it was reported enhanced expression of MMP-3
in IPF, compared with control lungs and MMP-3-null
mice were protected from bleomycin-induced pulmonary
fibrosis [35]. Interestingly, in vitro treatment of lung
epithelial cells with MMP-3 resulted in activation of the
b-catenin signaling pathway, via cleavage of E-cadherin,
with the subsequent induction of epithelial-mesenchymal
Figure 1 MMPs and TIMPs expression levels by microarray analysis from controls and IPF lungs. Increased genes are shown in
progressively brighter shades of yellow, and decreased genes are shown in progressively darker shades of blue. Genes shown in gray are not
different between the groups.
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in the pathogenesis of IPF, through the induction of
epithelial-mesenchymal transition.
MMPs may participate in the traffic of fibrocytes to the
IPF lungs
It is known that fibrocytes, bone-marrow derived progeni-
tor cells, are a source of fibroblasts/myofibroblasts that
participate in the mechanisms of wound healing and fibro-
sis in many tissues. Recently, we demonstrated the pre-
sence of fibrocytes in the lungs from patients with IPF,
and provided evidence for their principal mechanism of
chemotaxis, the CCL12/CXCR4 axis [5]. Lately, we found
that fibrocytes strongly express several MMPs including
MMP-2, MMP-9, MMP-8 and MMP-7 [36]. To elucidate
the role of MMP-8, MMP-2 and MMP-9 in fibrocytes
biology we tested the hypothesis that these enzymes may
participate in the process of tissue migration. In this con-
text, we found that the migration of fibrocytes through
collagen I is highly associated with the expression of col-
lagenase MMP-8 while its migration through basement
membrane-like proteins was associated to MMP-2 and
MMP-9 since both transmigration assays were blocked by
specific inhibitors. Therefore, synthesis of these enzymes
may play an important role in transendothelial and tissue
migration of fibrocytes and also contribute in the remodel-
ing of ECM during the development of IPF.
MMP-9 is associated with the lack of thy-1 receptor in
lung fibroblasts
MMP-9 is also elevated in IPF, and it is expressed by a
variety of cells including alveolar epithelial cells, neutro-
phils and fibroblasts in fibroblastic foci [27]. The finding
that lung fibroblasts in IPF are synthesizing MMP-9 is
intriguing since these cells do not express this enzyme in
vitro, but a recent finding in our laboratory open some
light to this result. It is well known that fibroblasts differ
in a variety of phenotypic features, including the expres-
sion of Thy-1 a glycophosphatidylinositol-linked glyco-
protein. In this context, it was shown that fibroblasts in
IPF lungs are Thy-1 negative, whereas most fibroblasts
from normal lungs are Thy-1 positive [37]. Recently, we
demonstrated that Thy-1 (-) lung fibroblasts stimulated
with TGF-b1 expressed MMP-9 while Thy-1 (+) cells did
not [38]. Moreover, treatment of Thy-1 (-) fibroblasts
with b-glycan, which sequester TGF-b, thereby function-
ing as a receptor antagonist, abolished MMP-9 induction.
TGF-b1-induced MMP-9 in Thy-1 (-) fibroblasts
depended on the activation of ERK1/2 signaling pathway
[38]. Therefore, it can be suggested that in the microen-
vironment of IPF lungs, the mesenchymal cells from the
fibroblasts/myofibroblasts foci, which do not express
Thy-1, stimulated by the epithelial-produced TGF-b1
synthesize MMP-9. Importantly, MMP-9 is able to
activate TGF-b contributing to enhance the pool of active
TGF-b [39]. Taken together, these findings indicate that
TGF-b induction of MMP-9 in Thy-1 (-) fibroblasts
could be part of a fibrogenic positive feedback loop.
Conclusion
Idiopathic pulmonary fibrosis is a devastating disease char-
acterized by epithelial cell activation and the expansion of
the fibroblasts/myofibroblasts population in the alveolar
septa and alveolar spaces which is followed by aberrant
deposit of extracellular matrix. The pathogenic mechan-
isms remain elusive, but a growing body of evidence sup-
ports that several matrix metalloproteinases are implicated
in the abnormal remodeling of the extracellular matrix
including basement membranes, although an antifibrotic
effect of some of them under certain circumstances can
not be ruled-out. In addition, the biological consequences
of the MMPs-cleavage of chemokines, cytokines, and
growth factors in the lung microenvironment are presently
unknown. A better understanding of the molecular
mechanisms that are involved in the pathogenesis of the
disease as well as those that regulate the local balance
between accumulation of extracellular matrix and their
degradation will be critical to set the MMPs in their exact
place. Also, an improved understanding of the complexity
of MMP proteolysis and their in-vivo substrate repertoires
will help to define the fibrosis-specific effects of MMPs in
IPF.
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